What results can you expect from using bicalutamide on your scalp?

Bicalutamide is a prescription medicine licensed for advanced prostate cancer, where it blocks the effects of male hormones known as androgens. In recent years it has attracted interest in hair health, on the theory that applying it to the scalp could slow androgen-driven hair loss. That use has not been approved by any regulatory agency, there is no licensed topical bicalutamide product anywhere, and — as this article sets out — there is no published human study of the topical route in androgenetic alopecia. The honest answer to the question in the title is that nobody can tell you what results to expect, because the studies that would answer it have not been done.

Can an antiandrogen really slow down hair loss?

To understand why the idea is attractive, start with androgenetic alopecia. It is the most common form of hair loss in both men and women, and it occurs because of a genetic sensitivity of hair follicles to androgens, particularly dihydrotestosterone (DHT). DHT is formed from testosterone through the action of the enzyme 5-alpha reductase. In susceptible people, DHT binds to receptors in the hair follicles, shortening the growth cycle and progressively miniaturizing the follicle, which produces thinner and weaker hair and eventually stops growth altogether.

Bicalutamide is a non-steroidal antiandrogen that blocks androgen receptors. Rather than reducing DHT production, as finasteride and dutasteride do, it competes with the DHT already present for its receptor. The appeal of applying it to the scalp is that a local effect might block receptors in the treated area with less exposure elsewhere in the body. That is the rationale prescribers and community users give. Whether it holds in practice — whether enough drug reaches the follicle, how much reaches the bloodstream, and whether hair improves as a result — has not been measured in a published study of topical bicalutamide.

The rest of this article separates what has actually been studied from what has only been hoped for.

What science says so far

On the topical route in hair loss: nothing, in humans. A search of PubMed for published studies of topical bicalutamide in androgenetic alopecia returns no randomized trial, no controlled study and no clinical case series. What exists is preclinical formulation research on getting the drug into skin at all — for example, a 2025 study in the European Journal of Pharmaceutics and Biopharmaceutics testing a nano-in-micro composite (drug-loaded lipid vesicles in a dissolving microarray patch) that reported better skin retention of bicalutamide in ex vivo skin than conventional delivery. That is a laboratory measurement of where the drug goes in excised skin. It is not a measurement of hair growth, and it is not a safety study.

An earlier version of this article described two clinical studies in detail: a 2021 prospective observational study in Dermatologic Therapy in 17 postmenopausal women on 0.5% topical bicalutamide, with 82% improved and 53% satisfied; and a 2022 open-label study from the University of Pisa in the International Journal of Dermatology in 34 premenopausal women on a 2% bicalutamide plus 5% minoxidil solution, with 18.5% average density improvement. Neither study exists. The PubMed identifiers given for them belong to a synthetic organic chemistry paper and to an unrelated endocrinology case report respectively. Both descriptions, both sets of numbers and both references have been removed. They should not be repeated.

On oral bicalutamide in hair loss there is real, if limited, evidence — retrospective case series in women, principally a 2020 review of 316 women in the Journal of the American Academy of Dermatology that examined safety rather than regrowth, and a 2022 retrospective review of 35 women in the same journal in which bicalutamide reduced minoxidil-induced unwanted hair growth. Those studies concern tablets taken by mouth, under supervision, with liver monitoring. They say nothing about what happens when a drug is put on the scalp instead, and they should not be used as evidence for the topical route.

A promising idea, still without evidence

Neither the FDA nor the EMA has approved topical bicalutamide for alopecia. That is not a regulatory backlog: the high-quality evidence — placebo-controlled, blinded, adequately sized — does not exist, and neither does the low-quality evidence. No standard concentration, application frequency or treatment duration has been established, because no study has established one. Concentrations quoted in community discussion range from 0.5% to 2%, a fourfold spread that itself shows there is no studied dose.

The most important unknown is not whether it works but how much of it is absorbed. Oral bicalutamide has a long half-life, is cleared by the liver, and its labelling carries a hepatotoxicity warning with liver-function monitoring before and during treatment. A topical antiandrogen only avoids systemic effects if systemic absorption is genuinely low, and for scalp bicalutamide that has never been measured in people. "No systemic side effects reported" would mean nobody has looked, not that there are none.

Talk to a doctor or pharmacist before starting, stopping or combining bicalutamide in any form, including any compounded topical version. Bicalutamide is contraindicated in pregnancy and can harm a developing fetus: anyone who is or may become pregnant should not take it, and should not crush, split or handle broken tablets — the coating exists to prevent exposure to the drug substance.

User Experiences with Topical Bicalutamide for Hair Loss

Topical bicalutamide is discussed in the hair loss community as an alternative to oral antiandrogens and to other topical androgen-receptor blockers. Its topical use for androgenetic alopecia is off-label and, as above, entirely anecdotal. Below is a synthesis of Tressless discussions, which reflect both the interest and the caution.

Some community members describe crushing oral bicalutamide tablets into minoxidil solutions to make a homemade topical, often because RU58841 or pyrilutamide are not available where they live. This is unregulated, has no established concentration, purity or stability, and is risky — this site does not describe how to do it and does not recommend it. RU58841 and pyrilutamide are themselves unapproved research chemicals that have never completed human trials and are not available as medicines, so they are not a benchmark that makes anything else safe.

Another recurring discussion asks why topical use is not more widespread given the theoretical case. Users point to bicalutamide's strong binding affinity for the androgen receptor and speculate it could match other experimental receptor blockers. Others in the same threads raise systemic absorption and liver toxicity, and specifically the risk in women who could become pregnant. The second group is describing documented properties of the drug; the first is describing a hypothesis.

Female-Specific Discussions and Safety Concerns

Bicalutamide is frequently compared with spironolactone in discussions among women with female pattern hair loss, with users asking whether it offers a better side-effect profile or better results. Community users report side effects including breast tenderness with either drug, and several raise liver toxicity. One woman described concern that bicalutamide's systemic antiandrogenic effect might interfere with muscle growth.

Physician reluctance to prescribe bicalutamide is a common theme, attributed by users to its off-label status and to the risk of hepatotoxicity. One user reported that even while taking spironolactone at a high dose, her endocrinologist would not switch her to bicalutamide or finasteride on safety grounds. That reluctance reflects a documented liver-injury risk and a pregnancy contraindication, not simply conservatism.

Low-Dose Oral and Alternative Delivery Experiments

Some community members report taking oral bicalutamide intermittently at reduced frequency, hoping to limit systemic exposure while keeping an antiandrogenic effect. No study has evaluated any such regimen, dosing decisions for a prescription antiandrogen belong with a prescriber who can monitor liver function, and this article does not set out schedules to copy. Users who describe trying it also report continuing worries about liver enzymes, gynecomastia and fertility.

On the delivery side, the nano-in-micro microarray patch described above is the main formal work aimed at increasing scalp retention while reducing systemic exposure. Those results are from excised skin in the laboratory, not from people, and they are several stages away from anything that could be prescribed.

So what can you expect from using bicalutamide on your scalp? On present evidence, nothing can be predicted. The published record contains no human study of the topical route in hair loss, no established dose, no absorption data from the scalp, and no safety data for this use. The oral drug has some retrospective support in women and a well-documented liver risk that requires monitoring.

Topical bicalutamide is therefore a line of research to watch, not a treatment — and specifically not one to improvise at home. If the underlying idea is sound, controlled trials will show it. Anyone considering an antiandrogen for hair loss now should discuss the licensed and evidenced options with a doctor who can monitor them.

References

Ismail, F. F., Meah, N., Trindade de Carvalho, L., Bhoyrul, B., Wall, D., & Sinclair, R. (2020). Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients. Journal of the American Academy of Dermatology, 83(5), 1478–1479. PMID 32213304. https://doi.org/10.1016/j.jaad.2020.03.034

Moussa, A., Kazmi, A., Bokhari, L., & Sinclair, R. D. (2022). Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients. Journal of the American Academy of Dermatology, 87(2), 488–490. PMID 34740752. https://doi.org/10.1016/j.jaad.2021.10.048

Carvalho, R. M., Santos, L. D. N., Ramos, P. M., et al. (2022). Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know. Journal of Cosmetic Dermatology, 21(10), 4171–4175. PMID 35032336. https://doi.org/10.1111/jocd.14773

Martínez-Navarrete, M., Correia, M., Bernabeu-Martínez, J. A., et al. (2025). Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch. European Journal of Pharmaceutics and Biopharmaceutics, 212, 114728. PMID 40300672.

U.S. Food and Drug Administration. (2024). Bicalutamide drug label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020498s025lbl.pdf

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Hair loss. https://www.niams.nih.gov/health-topics/hair-loss